Peptide before and after: trial results vs marketing photos

The short answer: real peptide before and after results exist only where a trial measured them. The GLP-1 drugs semaglutide and tirzepatide have large randomized trials showing mean weight loss of about 15% to 21% of body weight, and tesamorelin has trials showing about 15% less visceral belly fat. [1] [3] [5] For most other peptides marketed with before and after photos, including the Glow blend, GHK-Cu injections, BPC-157, and the Wolverine stack, no human trial has measured a before and after result at all.

This post compares measured outcomes with marketing photos. It gives FDA label facts only for approved drugs and no doses for unapproved peptides.

What does a real peptide before and after look like?

A trial result is a before and after photo taken of hundreds or thousands of people at once, with a comparison group that got a placebo. That comparison group is what makes the result believable: it shows how much change would have happened anyway from diet advice, the passing of time, and the effort of being in a study.

Three kinds of numbers matter:

• The average change, not the best one.
• The placebo change, which tells you how much of the result is the drug.
• What happens after stopping, which tells you whether the "after" lasts.

A marketing photo gives you none of these. It shows one person, chosen by the seller, with no comparison and no follow-up.

GLP-1 before and after: semaglutide and tirzepatide

These are the peptide drugs with the strongest before and after evidence.

Semaglutide. In STEP 1, 1,961 adults with obesity or overweight and no diabetes were randomized to weekly semaglutide or placebo, both with lifestyle support. At 68 weeks the mean weight change was minus 14.9% with semaglutide and minus 2.4% with placebo. [1] About half of the semaglutide group (50.5%) lost 15% or more of body weight, compared with 4.9% on placebo. [1]

Tirzepatide. In SURMOUNT-1, 2,539 adults without diabetes were randomized to one of three doses or placebo for 72 weeks. Mean weight change was minus 15.0%, minus 19.5%, and minus 20.9% across the three doses, compared with minus 3.1% on placebo. [3]

Those are averages. Some people lost much more and some lost little, which is exactly what a single photo hides. For how the two drugs compare directly, see semaglutide vs tirzepatide, and for the condition overview see obesity.

What happens after you stop a GLP-1?

The "after" photo is usually taken while someone is still on the drug. Two withdrawal trials show what happens next:

• STEP 4: after 20 weeks on semaglutide (mean loss 10.6%), people were randomized to keep going or switch to placebo. Over the next 48 weeks, those who continued lost another 7.9%, while those switched to placebo regained 6.9%. [2]
• SURMOUNT-4: after 36 weeks on tirzepatide (mean loss 20.9%), people who continued lost another 5.5% over 52 weeks, while those switched to placebo regained 14.0%. [4]

So a fair before and after for these drugs has three frames: before, on treatment, and after stopping.

Tesamorelin before and after: visceral fat, not weight

Tesamorelin is a growth hormone releasing factor analog with an FDA approval and a lawful prescription path today. It is approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. [6]

In a pooled analysis of two phase 3 trials with 806 patients, visceral fat changed by minus 24 square centimeters on tesamorelin versus plus 2 on placebo at 26 weeks, a treatment effect of about 15%, with no change in fat under the skin of the abdomen. [5] Patients who were switched to placebo after 26 weeks regained the visceral fat. [5]

That is a real, measured result, but it is a change you see on a CT scan more than in a mirror, and it was measured in people with HIV lipodystrophy, not in people using it for general fat loss. Our tesamorelin before and after post covers the numbers in detail, the HIV lipodystrophy page covers the condition, and the tesamorelin cost page covers pricing.

Glow peptide before and after: what is the evidence?

"Glow peptide before and after" is one of the most searched results queries in this space. The Glow blend is described as GHK-Cu, BPC-157, and TB-500, usually sold as an injection and marketed for skin.

No study has tested the Glow blend, so there is no measured before and after. The skin claims come from topical GHK-Cu: reviews describe small controlled cosmetic studies in which copper peptide creams tightened skin and reduced fine lines over about 8 to 12 weeks. [7] Those studies used creams, not injections, and were small and largely industry associated. [7] For the Klow version with KPV added, see Klow vs Glow.

GHK-Cu before and after: what the skin studies show

GHK-Cu is the one ingredient here with human skin data, and even that is mixed. In a small randomized study of 13 patients who had laser resurfacing around the mouth, blinded evaluators and computer analysis found no difference in redness, wrinkles, or overall skin quality between copper peptide skin care and a regimen without it; the only difference was higher patient satisfaction with the copper peptide products. [8]

That is a useful reminder: a person can feel that a product worked, and be honest about it, while objective measurement finds no difference. There is no human trial of injected GHK-Cu for any outcome. We compare the two routes in topical vs injectable GHK-Cu.

BPC-157 and Wolverine stack before and after

BPC-157 and TB-500, the two peptides in the Wolverine stack, are marketed with injury recovery stories. The evidence behind those stories is animal work:

• BPC-157 sped healing of a cut Achilles tendon in rats. [9] Human data are three small uncontrolled pilot reports with no control group; no randomized trial has reported. [15]
• Thymosin beta-4, the parent of TB-500, sped skin wound closure in rats. [11]

No trial has measured recovery in people using either peptide, and no study has tested the two together. A recovery story is also hard to judge because most soft tissue injuries improve with time and rehab alone. Our BPC-157 before and after post looks at those claims one by one.

Why before and after photos mislead

Even honest photos can mislead, for reasons that have nothing to do with the product:

• No comparison. Without a placebo group you cannot tell what would have happened anyway.
• Selection. Sellers show their best results, not the average.
• Other changes. Diet, training, sleep, lighting, posture, and camera angle all change between photos.
• Timing. The "after" is usually taken on treatment, before any regain.

Federal Trade Commission guides treat a testimonial about someone's results as a claim that those results are typical, and they expect the advertiser to have evidence to support it. [12] Our guide on how to read a peptide study explains how to check a claim yourself.

Which of these peptides can you get lawfully?

Semaglutide, tirzepatide, and tesamorelin are FDA approved drugs available with a prescription. The others are not:

• GHK-Cu (injectable): a withdrawn 503A nomination, not on the bulks list, so there is no lawful compounded injectable. Topical cosmetic GHK-Cu is lawful. [13]
• BPC-157 and TB-500: recommended for the 503A bulks list in July 2026, but FDA has not published a final rule. [14]
• Glow and the Wolverine stack: a blend inherits its strictest ingredient, so Glow has no lawful path and Wolverine waits on the rule. [13]

State telehealth and compounding rules are on our state law pages. For other results questions, see retatrutide before and after for a drug that is still in trials, and melanotan 2 before and after for a tanning peptide with no lawful path.

The general route is in how to get peptides prescribed, and what peptide therapy means separates approved drugs from compounded and research-labeled products.

The takeaway

When a peptide has a real before and after, it comes from a trial with a placebo group, an average result, and follow-up after stopping. The GLP-1 drugs and tesamorelin have that. Glow, injected GHK-Cu, BPC-157, and the Wolverine stack do not, so their photos are stories, not evidence. We will update this page when a trial changes that.